Burden of diabetes in Iran: how will it be affected by lifting of the economic sanctions?

The Lancet Diabetes and Endocrinology

Volumn 4, Issue 10, 2016, Pages 810-811

  Larijani, Bagher ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOTHERAPY; DIABETES MELLITUS; ECONOMIC ASPECT; ECONOMIC SANCTION; ECONOMICS; FINANCIAL BURDEN; HEALTH CARE; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IRAN; IRANIAN REVOLUTION; MEDICATION COMPLIANCE; MORBIDITY; MORTALITY RISK; NOTE; PREVALENCE; PRIORITY JOURNAL; WAR; COST OF ILLNESS; TRENDS;

COST OF ILLNESS; DIABETES MELLITUS; ECONOMICS; HEALTH POLICY; HUMANS; IRAN;

EID: 84990064463     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(16)30191-7     Document Type: Note

References (13)

1. 1 Vos, T, Barber, RM, Bell, B, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386 (2015), 743–800.
2. 2 NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participants. Lancet 387 (2016), 1513–1530.
3. 3 Norheim, OF, Jha, P, Admasu, K, et al. Avoiding 40% of the premature deaths in each country, 2010–30: review of national mortality trends to help quantify the UN sustainable development goal for health. Lancet 385 (2015), 239–252.
4. 4 Murray, CJ, Barber, RM, Foreman, KJ, et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. Lancet 386 (2015), 2145–2191.
5. 5 Institute for Health Metrics and Evaluation. GBD Compare, 2015, Institute for Health Metrics and Evaluation, Seattle http://vizhub.healthdata.org/gbd-compare/ (accessed May 8, 2016).
6. 6 Javanbakht, M, Baradaran, HR, Mashayekhi, A, et al. Cost-of-illness analysis of type 2 diabetes mellitus in Iran. PLoS One, 6, 2011, e26864.
7. 7 Hashemi, H, Larijani, B, Sayari, AK, et al. National action plan for prevention and control of NCDs and the related risk factors in the Islamic republic of Iran, 2015 to 2025, 2015, Ministry of Health and Medical Education, Tehran.
8. 8 Khashayar, P, Aalaa, M, Mahmoudzadeh, B, et al. Virtual clinic: core solution to diabetic patient relationship management. Iran J Public Health 42 (2013), 78–83.
9. 9 Nasli-Esfahani, E, Peimani, M, Rambod, C, Omidvar, M, Larijani, B, Developing a clinical diabetes guideline in diabetes research network in Iran. Iran J Public Health 43 (2014), 713–721.
10. 10 Mohammadi, D, US-led economic sanctions strangle Iran's drug supply. Lancet, 381, 2013, 279.
11. 11 Ministry of Health and Medical Education. Health system activities, health transformation plan achievements, 2015, Stationary Office, Tehran.
12. 12 Dabaghian, FH, Rassouli, M, Sadighi, J, Ghods, R, Adherence to prescribed medications of Iranian traditional medicine in a group of patients with chronic disease. J Res Pharm Pract 5 (2016), 52–57.
13. 13 Paes, AH, Bakker, A, Soe-Agnie, CJ, Impact of dosage frequency on patient compliance. Diabetes Care 20 (1997), 1512–1517.